Palmar plantar erythrodysesthesia epidemiology and demographics: Difference between revisions

	Palmar plantar erythrodysesthesia Microchapters
Home
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Palmar plantar erythrodysesthesia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural history, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Palmar plantar erythrodysesthesia epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Palmar plantar erythrodysesthesia epidemiology and demographics
CDC on Palmar plantar erythrodysesthesia epidemiology and demographics
Palmar plantar erythrodysesthesia epidemiology and demographics in the news
Blogs on Palmar plantar erythrodysesthesia epidemiology and demographics
Directions to Hospitals Treating Palmar plantar erythrodysesthesia
Risk calculators and risk factors for Palmar plantar erythrodysesthesia epidemiology and demographics

VisualWikitext

Latest revision as of 20:18, 17 July 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]

Overview

Palmar plantar erythrodysesthesia (PPE) has been reported to occur in 6 - 64% of patients treated with different chemotherapy regimens. However, the exact incidence of PPE is unknown, as most reports are isolated case reports or short case series.

Epidemiology and Demographics

Incidence

Based on some case series, palmar plantar erythrodysesthesia (PPE) has been reported to occur in 6 - 64% of patients treated with different chemotherapy regimens. ^[1]

References

↑ L. Hueso, O. Sanmartin, E. Nagore, R. Botella-Estrada, C. Requena, B. Llombart, C. Serra-Guillen, A. Alfaro-Rubio & C. Guillen. "[Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases]". Actas dermo-sifiliograficas. PMID 18394404.

[1] L. Hueso, O. Sanmartin, E. Nagore, R. Botella-Estrada, C. Requena, B. Llombart, C. Serra-Guillen, A. Alfaro-Rubio & C. Guillen. "[Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases]". Actas dermo-sifiliograficas. PMID 18394404.

[1]

@@ Line 1: / Line 1: @@
+__NOTOC__
 {{Palmar plantar erythrodysesthesia}}
-{{CMG}}, Zain Fatiwala M.D.
+{{CMG}}; {{AE}} {{MC}}
 ==Overview==
-PPE occurs in 6-42% of patients receiving chemotherapy.<ref name="pmid20614462" /> In BMT patients, there is a 35% incidence of PPE and may be due to the use of high doses of chemotherapy with addition of total body irradiation.<ref name="pmid3527075">{{cite journal| author=Crider MK, Jansen J, Norins AL, McHale MS| title=Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. | journal=Arch Dermatol | year= 1986 | volume= 122 | issue= 9 | pages= 1023-7 | pmid=3527075 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3527075  }}</ref>
+Palmar plantar erythrodysesthesia (PPE) has been reported to occur in 6 - 64% of [[Patient|patients]] treated with different [[chemotherapy]] regimens. However, the exact [[incidence]] of PPE is unknown, as most reports are isolated [[Case report|case reports]] or short [[case series]].
-==Epidemiology and demographics==
+==Epidemiology and Demographics==
-PPE occurs in 6-42% of patients receiving chemotherapy.<ref name="pmid20614462">{{cite journal| author=Baack BR, Burgdorf WH| title=Chemotherapy-induced acral erythema. | journal=J Am Acad Dermatol | year= 1991 | volume= 24 | issue= 3 | pages= 457-61 | pmid=2061446 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2061446  }}</ref>
+===Incidence===
-Several authors have reported that the incidence of PLD-associated hand and foot syndrome for patients with any grade of PPE is about 50% and for patients with grade 3 and grade 4 PPE the incidence is about 20%  for a PLD dose of 50 mg/m2 every 4 weeks <ref name="pmid14998846">{{cite journal| author=O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A et al.| title=Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. | journal=Ann Oncol | year= 2004 | volume= 15 | issue= 3 | pages= 440-9 | pmid=14998846 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14998846  }}</ref>, <ref name="pmid11454878">{{cite journal| author=Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ| title=Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. | journal=J Clin Oncol | year= 2001 | volume= 19 | issue= 14 | pages= 3312-22 | pmid=11454878 | doi=10.1200/JCO.2001.19.14.3312 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11454878  }}</ref>. According to evidence, it has been determined that a dose of 40 mg/m2 every 4 weeks is at present considered equally effective and less toxic. This has become a preferred dosage<ref name="pmid17229768">{{cite journal| author=Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G| title=Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). | journal=Ann Oncol | year= 2007 | volume= 18 | issue= 7 | pages= 1159-64 | pmid=17229768 | doi=10.1093/annonc/mdl477 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17229768  }}</ref>.
+* Based on some [[case series]], palmar plantar erythrodysesthesia (PPE) has been reported to occur in 6 - 64% of [[Patient|patients]] treated with different [[chemotherapy]] regimens. <ref>{{Cite journal
+ | author = [[L. Hueso]], [[O. Sanmartin]], [[E. Nagore]], [[R. Botella-Estrada]], [[C. Requena]], [[B. Llombart]], [[C. Serra-Guillen]], [[A. Alfaro-Rubio]] & [[C. Guillen]]
+  | title = &#91;Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases&#93;
+  | journal = [[Actas dermo-sifiliograficas]]
+ | pmid = 18394404
+}}</ref>
-In BMT patients, there is a 35% incidence of PPE and may be due to the use of high doses of chemotherapy with addition of total body irradiation.<ref name="pmid35270752">{{cite journal| author=Crider MK, Jansen J, Norins AL, McHale MS| title=Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. | journal=Arch Dermatol | year= 1986 | volume= 122 | issue= 9 | pages= 1023-7 | pmid=3527075 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3527075  }}</ref>
 ==References==
 {{reflist|3}}